The phagocytic-bactericidal capacity (PBC) of human polymorphonuclear leulkocytes (PMNs) for strains of Klebsiella (K) and of Enterococcus (E) was unaffected in vitro by the presence of 100 ug of either hydrocortisone (HC) or of methylprednisolone (MP) per ml in the medium. At higher concentrations (500 to 2,000 ug/ml) both compounds impaired PBC-K and PBC-E, but the latter was less sensitive to steroid-induced inhibition. In addition to interfering with intracellular killing of both organisms by PMNs, 2,000 Mg of HC per ml also inhibited ingestion of E, although not of K. Steroid-induced inhibition of PBC-K in vitro was completely abolished by increasing the concentration of serum used as opsonin. The PBC-K of human PMNs obtained 30 min after intravenous injection of 1 g of MP was unimpaired in vitro in the presence of 10 to 90% simultaneously obtained autologous serum containing 42 jg of MP per ml. These findings suggest that short-term, high-dosage administration of MP is unlikely to produce clinically significant impairment of intraleukocytic bacterial killing.
The short-term administration of massive dosages of corticosteroids has been advocated as a therapeutic adjunct in patients with a variety of disorders including overwhelming gramnegative sepsis (4) , and for such purposes as the prophylaxis of "pump lung" in patients undergoing open heart surgery (1). However, the efficacy as well as the potential risks (9) of this relatively new mode of steroid administration remain controversial (10, 16) . The recent demonstration that very high concentrations (2.1 mM) of hydrocortisone (HC) may interfere with intraleukocytic killing of microorganisms in vitro (14) suggests that host defenses against bacterial infection in patients receiving short courses of massive doses of highly potent synthetic corticosteroids such as methylprednisolone (MP) might also be impaired in vivo via a similar mechanism.
We have conducted in vitro as well as in vivo experiments, and have obtained results which indicate that neither HC nor MP reduces the phagocytic and bactericidal capacity (PBC) of polymorphonuclear leukocytes (PMNs) at concentrations likely to be achieved with currently employed dosage schedules; that much higher steroid concentrations impair PBC for strains of Klebsiella (PBC-K) and Enterococcus (PBC-E) ' (Fig. 3) than the same concentration of HC. However, as noted with HC, 100 jig of MP per ml did not diminish PBC-K significantly (P > 0.05). PBC-E was observed to be less sensitive to the inhibiting effect of MP (Fig. 4) than was PBC-K, and only concentrations of 1,000 ,g/ml (P < 0.05) and 2,000 ,g/ml (P < 0.05) significantly inhibited PBC-E. No significant difference was detected between the PBC-E inhibition produced by HC and MP (P > 0.2).
Experiments employing diff'erential centrifu- induced by HC (2,000 ug/ml) and by MP (2,000 jsg/ml), respectively, which was observed in the presence of 10% serum. The same concentration of serum in the absence of PMNs did not inhibit bacterial growth. In contrast to these findings, the inhibition of PBC-E induced by effective concentrations of either steroid was not reversed by 30% (Fig. 6) To determine which fraction of the added serum was responsible for the reversal of steroid-induced PBC-K impairment, fresh serum was fractionated on a Sephadex G-200 column into 4S, 5S, 7S, 11S, and 19S components using standard methods (7). The resulting fractions were then compared with whole serum for their ability to reverse the inhibition of PBC-K induced by 2,000 ,g of HC per ml. Each serum fraction was tested at the same final concentration calculated to be present at the corresponding concentration of whole serum. After 60 min of incubation, only 4% of the organisms survived when fractions 4S or 5S were added to the test system, thus reproducing the reversal of HCinduced inhibition of PBC-K which resulted from the addition of the corresponding concentration (60%) of whole serum. When fractions 7S, llS, or 19S were used, bacterial survival after 60 min was 40% or greater.
Effect of in vivo MP administration on PBC in vitro. Despite the finding that steroid concentrations exceeding those achieved clinically (17) failed to inhibit PBC in vitro in the presence of 30 and 60% serum, an experiment was done to determine whether impaired PBC might nevertheless be demonstrable in vitro after intravenous (i.v.) injection of a very large single dose of MP. Such a circumstance might result, for example, from the production in vivo of steroid metabolites absent from the in vitro system and capable of inhibiting PBC in vitro even in the presence of relatively high serum concentrations.
Therefore, 30 min after the i.v. injection of 1 g of MP, blood for phagocytosis studies was obtained from the same subject who had provided the PMNs and serum employed in the previous studies. The 30-min time period before sampling was arbitrarily selected to allow time for in vivo production of MP metabolites, and to insure the persistence of pharmacological serum MP levels. To avoid the possible removal from the in vitro system by dilution of MP or other potentially active substances present in vivo, whole serum rather than GH was used for washing and diluting the PMNs used in this experiment. PMNs and serum obtained prior to the steroid injection were processed identically and served as a control, both with and without the addition of (14) . Conversely, Allison and Adcock (2) found that phagocytosis and intracellular killing of pneumococci by PMNs obtained from healthy human donors who had received 1 to 2 mg of prednisone per kg per day for 4 days prior to testing were unimpaired. It seems pertinent to point out, however, that in these studies, as well as in the experiments reported here, the duration of steroid treatment was much shorter than that generally thought to be associated with an increased risk of clinically apparent infection. Accordingly, the relevance of these experimental data to the pathogenetic mechanisms underlying such infections is limited at best. On the other hand, such data would seem relevant to mechanisms which might enhance the susceptibility of uninfected patients to pyogenic infection by shortterm, high-dosage steroid therapy; such an enhanced susceptibility has not been documented, however, despite the increasingly frequent use of such therapy in a variety of clinical settings (1, 4) .
Our data confirm the observations of Mandell et al. (14) that concentrations of HC which do not appear to affect ingestion of Klebsiella by human PMNs nevertheless do impair intracellular killing of these organisms in vitro. However, the concentration of HC required to produce such impairments in our studies greatly exceeds the serum concentrations produced by parenteral injection of large doses of HC to humans (17) . Since the number of colony-forming bacteria present in control tubes which lacked PMNs or opsonin consistently increased two-to fourfold during the standard 60-min observation period in nearly every experiment, it seems likely that even 2,000 mg of HC per ml produced only incomplete impairment of PBC-K and PBC-E. The same high concentrations of MP were also necessary to produce impairment of PBC-K despite the fact that MP is considerably more potent than HC in many of its other biological properties (11) . Inhibition of PBC-K was not observed in vitro after the addition of 100 ug of either steroid per ml. PBC-E was considerably less sensitive to both HC and MP than PBC-K. Enterococci produce H202 (13), a substance believed to participate in the intracellular killing of phagocytosed bacteria; these organisms might thus be expected to be more susceptible to intracellular destruction than Klebsiella and other bacteria which do not produce H202 (13) under conditions of impaired endogenous H202 production by PMNs. Our results are consistent with such a hypothesis.
The data presented in Table 1 also indicate that at a concentration of 2,000 gg/ml, hydrocortisone induced interference with PMN ingestion of enterococci but not of Klebsiella. They further suggest (but do not prove) that, at this concentration, HC-induced interference with H202 production by the ingested enterococci may have contributed to their intracellular survival. The observation that the presence of additional serum in the in vitro test system completely reversed the ability of even very high concentrations of HC and MP to inhibit PBC-K reiterates the need for caution in extrapolating data obtained under relatively unphysiological in vitro test conditions to pathophysiological mechanisms prevailing in vivo or to clinical therapeutics. It seems possible that the failure of Allison and Adcock (2) to observe steroidinduced impairment of PBC for pneumococci may have been due in part to the fact that they employed an in vitro phagocytosis system containing a high concentration of autologous serum.
The possibility that the observed seruminduced reversal of steroid-induced PBC inhibition reflects binding of HC and/or MP to serum proteins is suggested by the finding that this reversal was also produced by adding increased amounts of the albumin-containing 4S and 5S serum fractions alone. Large amounts of HC and of MP are known to bind to serum albumin, although with a low affinity (18) , and it seems possible that such binding might well modify the biological activity of even large concentrations of steroids in vivo as well as in vitro. Because the steroid concentrations tested were greatly in excess of the binding capacity of the corticosteroid-binding globulin (transcortin) 
